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Abstract
Background: Acute kidney injury (AKI) is frequently detected in deceased donors (DDs), and it could be associated
with adverse clinical outcomes in corresponding kidney transplant recipients (KTRs). In this regard, we sought to
identify which criteria is better between the KDIGO and AKIN criteria for the diagnosis of AKI in DDs in the
prediction of clinical outcomes after kidney transplantation (KT).
Methods: Two hundred eighty-five cases of deceased donor kidney transplantation (DDKT) were included. We
divided them into three groups; the non-AKI by both KDIGO and AKIN criteria group (n = 120), the AKI by KDIGO
only group (n = 61), and the AKI by both criteria group (n = 104) according to the diagnosis of AKI using the KDIGO
and AKIN criteria in the corresponding 205 DDs. We compared the development of delayed graft function (DGF),
the change in allograft function, the allograft survival among the three groups.
Results: The incidence of DGF was significantly higher in the AKI by KDIGO only and the AKI by both criteria
groups than in the non-AKI by both criteria group (P < 0.05 each). But no difference was detected between the AKI
by KDIGO only group and the AKI by both criteria group (P > 0.05). Therefore, the KDIGO criteria had a better
predictive value for DGF occurrence than the AKIN criteria (Area under the curve = 0.72 versus 0.63, P < 0.05) in
Receiver Operation Characteristic analysis. On comparison of allograft function, the AKI by KDIGO only and the AKI
by both criteria groups showed a significantly deteriorating pattern by 6 months after KT in comparison with the
non-AKI by both criteria group (P < 0.05). However, the differences disappeared at 1 year from KT and long-term
allograft survival did not differ among the three groups. AKI stage either by KDIGO or AKIN in DDs did not affect
long-term allograft survival in corresponding KTRs as well.
Conclusions: The KDIGO criteria may be more useful for predicting DGF than the AKIN criteria. However, AKI or AKI
stage by either criteria in DDs failed to affect long-term allograft outcomes in KTRs.
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Background
The imbalance between donors and recipients of kidney
transplantation (KT) promoted the introduction of vari-
ous strategies to increase the potential donor pool for
transplantation [1, 2]. In this regard, the use of kidneys
from deceased donors (DDs) with acute kidney injury
(AKI) has been proposed as an important strategy to
solve donor shortage [3–10]. However, specific guide-
lines or standardized classification methods to determine
the severity of AKI in deceased donors have not been
established, even though the use of kidneys from DDs
with AKI may induce adverse post-transplant outcomes,
for example higher incidence of delayed graft function
(DGF) recovery [11–13].
Meanwhile, standardized classification systems that rep-
resent the status of AKI, have been developed and widely
applied in the clinical practice [14]. Initially, the RIFLE
(Risk, Injury, Failure, Loss, End-Stage Kidney Disease) cri-
teria were developed by the Acute Dialysis Quality Initiative
group and a modification of the RIFLE criteria, known as
the AKIN (AKI Network) classification system, was pro-
posed later [15, 16]. More recently, the KDIGO (Kidney
Disease: Improving Global Outcomes) proposed a new def-
inition and classification of AKI based on both the RIFLE
and AKIN criteria, and it showed a better prediction of the
prognosis of AKI in hospitalized patients [17, 18].
Previously, we found that application of the AKIN cri-
teria for diagnosis of AKI in DDs was useful to predict
the development of delayed graft function (DGF) recov-
ery in the corresponding kidney transplant recipients
(KTRs) [5]. However, the KDIGO criteria, which showed
better performance compared to the AKIN criteria in
the general population, has not been adopted in this
field till now. In this regard, we used the KDIGO criteria
for the diagnosis of AKI in DDs, and compared its per-
formance in the prediction of DGF or post-transplant
outcomes in corresponding KTRs with the AKIN
criteria.
Methods
The aim and study populations of the study
The aim of this study is to identify which criteria are
better between the KDIGO and AKIN criteria for the
diagnosis of AKI in DDs in the prediction of clinical
outcomes after KT. We included deceased donor kid-
ney transplantation (DDKT) performed at Seoul St.
Mary’s hospital and Uijeongbu St. Mary’s hospital be-
tween September 1996 and March 2014. During this
period, 426 kidneys were harvested from 213 DDs in
Seoul St. Mary’s hospital. Among them, 16 kidneys
from 8 potential donors were discarded because they
were not found to be suitable for transplantation on
donor kidney biopsy (5 cases of advanced chronic
change, 1 case of IgA nephropathy, 1 case of
thrombotic microangiopathy) or because of underlying
disease (1 case of autosomal dominant polycystic kid-
ney disease). Therefore, 410 kidneys from 205 DDs
were used for KT. Among them, 125 kidneys were
transferred to another institution for KT according to
the organ distribution rule in Korea. Finally, 285 kid-
neys were transplanted in Seoul St. Mary’s hospital (n
= 265) or Uijeongbu St. Mary’s hospital (n = 20). We
included these 205 donors and 285 corresponding
KTRs in this analysis (Fig. 1).
Diagnosis of AKI in DDs
According to the KDIGO or AKIN criteria, we deter-
mined the stage or severity of AKI in 205 DDs as de-
scribed in previous reports [16, 19]. Briefly, according to
the KDIGO criteria, stage 1 encompasses a serum cre-
atinine (SCR) level increase of ≥0.3 mg/dL within 48 h
or increase in SCR to ≥1.5 times baseline, which is
known or presumed to have occurred within 7 days, or a
reduction in urine output (<0.5 mL/kg/h for 6 h); stage
2, increase in SCR to 2.0-2.9 times baseline or a reduc-
tion in urine output (<0.5 mL/kg/h for 12 h); stage 3, in-
crease in SCR to 3.0 times baseline or to ≥4.0 mg/dL, or
receipt of renal replacement therapy (RRT) or a reduc-
tion in urine output (<0.3 mL/kg/h for 24 h or anuria
for 12 h). According to the AKIN criteria, stage 1 is de-
fined as an absolute SCR increase of ≥ 0.3 mg/dL or in-
crease to ≥ 1.5-2 times or a reduction in urine output
(<0.5 mL/kg/h for 6 h); stage 2, increase in SCR to >2-3
times or a reduction in urine output (<0.5 mL/kg/h for
12 h); stage 3, increase in SCR to >3 times or to
≥4.0 mg/dL with an acute increase of at least 0.5 mg/dL
or receipt of RRT or a reduction in urine output
(<0.3 mL/kg/h for 24 h or anuria for 12 h). Two values
of SCR within 48 h were used in all AKIN criteria
stages.
Classification of donors and recipients according to the
AKIN or KDIGO criteria
Figure 1 shows the distribution of DDs and correspond-
ing KTRs according to the diagnosis of AKI by the
KDIGO or AKIN criteria. Out of the 205 DDs, 93 cases
(45.4%) were diagnosed as non-AKI and 73 donors
(35.6%) were diagnosed as AKI by both the KDIGO and
AKIN criteria. However, 39 cases (19.0%) were diag-
nosed as AKI by the KDIGO criteria, but they did not
meet the definition of AKI according to the AKIN cri-
teria. After excluding the 125 kidneys that were trans-
ferred to other institutions, 120 patients received
kidneys from donors diagnosed with non-AKI by both
criteria (the non-AKI by both criteria group) and 104
patients received kidneys from donors diagnosed with
AKI by both criteria (the AKI by both criteria group).
The remaining 61 patients received kidneys from
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donors diagnosed with AKI by KDIGO only (the AKI
by KDIGO only group). Among these three groups, we
compared the baseline characteristics of donors as well
as those of recipients (Tables 1, and 2).
In addition, we performed two group analysis be-
tween the AKI group and the non-AKI group accord-
ing to the diagnosis of AKI by the KDIGO or AKIN
criteria, respectively. Therefore, in the two group ana-
lysis based on the KDIGO criteria, the AKI group in-
cluded 165 patients (the AKI by both criteria plus the
AKI by KDIGO only groups), and 120 patients
belonged to the non-AKI group (the non-AKI by both
criteria group). Based on the AKIN criteria, only 104
KTRs (AKI by both criteria) belonged to the AKI
group and the remaining 181 KTRs (the non-AKI by
both criteria plus the AKI by KDIGO only groups)
belonged to the non-AKI group (Fig. 1).
Clinical parameters and outcomes
We retrospectively reviewed the medical records of
all patients and collected baseline data of the donors
including age, sex, body mass index (BMI) (kg/m2),
history of diabetes mellitus and hypertension, cause of
death, last-day urine volume, central venous pressure
and mean arterial pressure from the day of admission
to the day of KT. In addition, we collected the base-
line data of the recipients: age, sex, BMI, primary
renal disease, duration of dialysis, number of previous
KT, percentage of panel-reactive antibodies (PRAs),
number of human leukocyte antigen (HLA) mis-
matches, type of induction therapy, maintenance im-
mune suppressants, and cold ischemic time.
The primary outcome of this study was the inci-
dence of DGF in KTRs according to the diagnosis of
AKI by the KDIGO or AKIN criteria in correspond-
ing DDs. DGF was defined as dialysis requirement
within the first week after KT [20]. Secondary out-
come included the allograft function during post-
transplant 1 year (3 days, 1 week, 2 weeks, 1 month,
3 months, 6 months, and 1 year after KT) determined
as the estimated glomerular filtration rate (eGFR)
using the modification of diet in renal disease
Fig. 1 Patient algorithm and distribution in this study. Out of the 213 DDs, 8 cases were excluded because they were not suitable for kidney donation.
The remaining 205 cases were divided into three groups; the non-AKI by both KDIGO and AKIN criteria group, the AKI by KDIGO only group, and the
AKI by both KDIGO and AKIN criteria group. Out of the 410 kidneys harvested from these DDs, 125 kidneys were transferred to another institution, and
285 kidneys were transplanted in our institutions. Each KTR also belonged to one of the three groups (the non-AKI by both criteria group, the AKI by
KDIGO only group, and the AKI by both criteria group) according to the group of corresponding DDs. TMA, thrombotic microangiopathy; ADPKD, auto-
somal dominant polycystic kidney disease; AKI, acute kidney injury; KDIGO, kidney disease: improving global outcome; AKIN, acute kidney injury net-
work; KTRs, kidney transplant recipients, DDs, deceased donors. *Transferred to another institution by the rule of organ distribution in Korea
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(AKI by KDIGO only vs.
Non-AKI by both)
P value
(AKI by both vs.
Non-AKI by both)
P value
(AKI by KDIGO only
vs. AKI by both)
Male 66 (55.0) 37 (61) 53 (51.0) 0.5 0.5 0.2
Age (years) 46.5 ± 8.0 48.0 ± 9.8 49.1 ± 11.3 0.3 0.05 0.5
Retransplant 13 (10.8) 8 (13) 8 (7.7) 0.7 0.4 0.3
BMI (kg/m2) 22.7 ± 3.3 22.8 ± 3.0 22.7 ± 3.6 0.8 0.9 0.9
Primary renal disease
DM 12 (10.0) 11 (18) 16 (15.4) 0.1 0.2 0.7
Hypertension 24 (20.0) 13 (21) 34 (32.7) 0.8 0.03 0.1
GN 55 (45.8) 23 (38) 33 (31.7) 0.3 0.03 0.4
Others 29 (24.2) 14 (23) 21 (20.2) 0.9 0.5 0.7
Duration of dialysis
(years)
7.1 ± 4.9 6.0 ± 4.1 6.6 ± 4.2 0.1 0.4 0.4
PRA (%) 13.1 ± 26.3 15.6 ± 29.6 12.3 ± 26.6 0.6 0.8 0.5
HLA MN 3.9 ± 1.1 3.8 ± 0.9 4.0 ± 1.3 0.6 0.4 0.2
Cold ischemic
time (minutes)
193.2 ± 86.5 201.7 ± 108.7 230.8 ± 121.9 0.6 0.01 0.1
Induction therapy 0.2 0.01 0.4
ATG 10 (8.3) 9 (15) 21 (20.2)
Basiliximab 110 (91.7) 52 (85) 83 (79.8)
Immunosuppressant
Cyclosporine 18 (15.0) 11 (18) 9 (8.7) 0.6 0.1 0.08
Tacrolimus 101 (84.2) 50 (82) 95 (91.3) 0.7 0.1 0.08
Sirolimus 1 (0.8) 0 (0) 0 (0) 0.9 0.9
Note: values for categorical variables are given as number (percentage); for continuous variables, as mean ± standard deviation
Abbreviations: AKI acute kidney injury, KDIGO kidney disease: improving global outcomes, AKIN acute kidney injury network, BMI body mass index, DM diabetes
mellitus, GN glomerulonephritis, PRA panel reactive antibody, HLA human leukocyte antigen, MN mismatch number, ATG anti-thymocyte globulin








(AKI by KDIGO only vs.
Non-AKI by both)
P value
(AKI by both vs. Non-
AKI by both)
P value
(AKI by KDIGO only vs.
AKI by both)
Male 60 (64.5) 27 (69) 52 (71) 0.6 0.4 0.8
Age (years) 40.2 ± 15.6 44.5 ± 14.1 46.3 ± 12.1 0.1 0.005 0.5
BMI (kg/m2) 22.2 ± 3.9 24.6 ± 4.0 22.8 ± 3.0 0.005 0.3 0.02
Hypertension 16 (17.2) 6 (15.4) 14 (19) 0.8 0.7 0.6
DM 4 (4.3) 1 (2.6) 8 (11.0) 0.9 0.1 0.1
Urine output
(ml/day)ª
4771.6 ± 3625.9 4840.8 ± 3647.3 4082.1 ± 3335.1 0.9 0.2 0.3
Cause of death
CVA 52 (56) 23 (59) 42 (58) 0.7 0.8 0.9
Trauma 26 (28.0) 12 (31) 23 (32) 0.7 0.6 0.9
Others 15 (16) 4 (10) 8 (11.0) 0.4 0.3 0.9
CVP (cmH2O)ª 6.9 ± 3.7 7.3 ± 3.7 7.3 ± 3.6 0.6 0.5 0.9
MAP
(mmHg)ª
88.1 ± 14.8 92.9 ± 17.8 88.5 ± 16.3 0.1 0.9 0.2
Note: values for categorical variables are given as number (percentage); for continuous variables, as mean ± standard deviation
Abbreviations: AKI acute kidney injury, KDIGO kidney disease: improving global outcomes, AKIN acute kidney injury network, BMI body mass index, DM diabetes
mellitus, CVA cerebrovascular accident, CVP central venous pressure, MAP mean arterial pressure
ªDuring the last 24 h before kidney transplantation
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(MDRD) equation [21], and long-term allograft sur-
vival rates.
We compared the clinical outcomes in two group ana-
lysis between the AKI group and the non-AKI group by
the KDIGO or AKIN criteria, respectively, and we also
compared these outcomes among the three groups; non-
AKI by both criteria; AKI by KDIGO only, and AKI by
both criteria.
Statistical methods
Statistical analyses were performed by using PASW
Statistics for Windows, Version 18 (SPSS Inc., Chicago,
IL, USA). Data are presented as mean ± standard devi-
ation (SD), or counts and percentages, depending on
the data type. The comparison between the AKI and
non-AKI groups was analyzed using the Student t test
or One-way ANOVA test for numerical values and the
χ2 test for categorical data. All continuous variables
were tested for normal distribution using the Shapiro-
Wilk test and were expressed as the mean ± SD. Cat-
egorical variables are presented as the percentage of
the number of cases. Receiver Operation Characteristic
(ROC) analysis was used to calculate the predictability
of each AKI criteria for the development of DGF in
KTRs. We used a non-parametric test, the Mann-
Whitney U test, for comparison of allograft function
assessed by the MDRD equation. After univariate ana-
lysis of the risk factors for DGF, significant variables
were analyzed by multivariate logistic regression ana-
lysis. Allograft survival rates were calculated using
Kaplan-Meier estimates and patient death was cen-
sored in this analysis. Differences between survivals
were calculated by log-rank analysis. Significant vari-
ables for allograft survival were analyzed by the Cox
regression hazard model. P < 0.05 was considered sta-
tistically significant.
Results
Comparison between the KDIGO and AKIN Criteria for the
Detection of AKI Severity in DDs
Out of the 112 cases (54.6%) of AKI diagnosed by the
KDIGO criteria, 42.8% (48/112) cases were stage 1,
29.5% (33/112) cases were stage 2, and 27.7% (31/112)
cases were stage 3 (Fig. 2a). According to the AKIN cri-
teria, out of the 73 (35%) cases of AKI, 71.2% (52/73)
cases were stage 1, 13.7% (10/73) cases were stage 2, and
15.1% (11/73) cases were stage 3 (Fig. 2b). Figure 2c
shows a significant association between KDIGO and
AKIN in regard to the distribution of AKI stage (Pear-
son’s correlation coefficient; 0.669, p < 0.001). However,
discrepancy between the two criteria was detected in
35.1% (72/205) of cases. Out of the 132 non-AKI donors
by AKIN, 16.7% (n = 22) donors were stage 1, 6.8% (n =
9) donors were stage 2, and 6.1% (n = 8) donors were
stage 3 AKI according to the KDIGO criteria. Out of the
52 stage 1 donors by AKIN, 36.5% (n = 19) donors were
stage 2 and 17.3% (n = 9) donors were stage 3 according
to the KDIGO criteria. Among the 10 stage 2 donors by
AKIN, 2 donors were stage 1 and 3 donors were stage 3.
All stage 3 donors (n = 16) by AKIN were also defined as
stage 3 by the KDIGO criteria.
Comparison between the KDIGO and AKIN criteria for the
prediction of the development of DGF
DGF developed in 57 out of the 285 patients; hence the
incidence of DGF was 20%. In the analysis using the
KDIGO criteria for the diagnosis of AKI in DDs, DGF
Fig. 2 Diagnosis of AKI or AKI stage in DDs according to the (a)
KDIGO or (b) AKIN criteria. Please note that 39 donors belonging to
the AKI by KDIGO only group as shown in Fig. 1 belonged to the
non-AKI group in patient distribution by the AKIN criteria; hence the
proportion of AKI was higher in the donor distribution according to
the KDIGO criteria in comparison with the AKIN criteria. c The AKI
stage in KDIGO showed a significant association with that in the
AKIN criteria (Pearson’s correlation coefficient; 0.669, p < 0.001). How-
ever, there was discordance between these two criteria in 35.1%
(72/205) of the total DDs. AKI, acute kidney injury; DDs, deceased do-
nors; KDIGO, kidney disease: improving global outcome; AKIN, acute
kidney injury network
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developed more frequently in the AKI group than in the
non-AKI group (29.7% versus 6.7%; P < 0.05; Fig. 3a),
and also in another analysis using the AKIN criteria, the
incidence of DGF was significantly higher in the AKI
group than in the non-AKI group (29.8% versus 14.4%;
P < 0.05; Fig. 3b). When we compared the development
of DGF among the three groups (non-AKI by both cri-
teria, AKI by KDIGO only, and AKI by both criteria
groups), the incidence of DGF was significantly lower in
the non-AKI by both criteria group (6.7% (8/120)) in
comparison with the AKI by KDIGO group (29.5% (18/
61)) or the AKI by both criteria group (29.8% (31/104))
(P < 0.001 for each). However, it did not show any sig-
nificant difference between the AKI by KDIGO only and
the AKI by both criteria groups (P = 1.0) (Fig. 3c).
Comparison between the KDIGO and AKIN criteria for the
prediction of DGF
We investigated whether the diagnosis of AKI by KDIGO
or AKIN in DDs can significantly predict the development
of DGF in corresponding KTRs. In univariate analysis,
male donor, and AKI by the KDIGO criteria and AKI by
the AKIN criteria in DDs were significant risk factors for
the development of DGF in corresponding KTRs. In
multivariate analysis, diagnosis of AKI by the KDIGO or
AKIN criteria in DDs was still an independent risk factor
for the development of DGF in corresponding KTRs
(Table 3). For making a comparison of the predictive value
for DGF in KTRs, we performed ROC curve analysis. Fi-
nally, the KDIGO criteria showed better prognostic accur-
acy in the prediction of the development of DGF
compared to the AKIN criteria (area under the curve =
0.721 versus 0.636; P = 0.01, z statistics; 2.466, Fig. 3d).
Comparison of the change in allograft function during
post-transplant 1 year
Figure 4 shows the comparison of the changing pattern
of allograft function assessed by the MDRD equation
during post-transplant 12 months between the AKI
group and the non-AKI group. At each time-point upto
Fig. 3 Comparison of the development of DGF between the AKI and non-AKI groups according to the diagnosis of AKI by either the (a) KDIGO
or (b) AKIN criteria in corresponding DDs. Please note that the incidence of DGF was significantly higher in the AKI group irrespective of the cri-
teria applied for the diagnosis of AKI in DDs. c Comparison of DGF among the three groups; non-AKI by both criteria, AKI by KDIGO only, and AKI
by both criteria groups. Please note that the incidence of DGF in the AKI by KDIGO only group was very similar to that in the AKI by both criteria
group, and it was significantly higher than that in the non-AKI by both criteria group. d Comparison of the predictive value for DGF between the
KDIGO and AKIN criteria. Please note that the AUC was significantly larger in KDIGO (0.72) in comparison with the AKIN criteria (0.63). DGF, de-
layed graft function; AKI, acute kidney injury; DDs, deceased donors; KDIGO, kidney disease: improving global outcome; AKIN, acute kidney injury,
DDKT, deceased donor kidney transplantation; AUC, area under the curve. *P < 0.05 compared with non-AKI group
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6 months from KT, allograft function was significantly
lower in the AKI group in comparison with the non-
AKI group in both analyses using the KDIGO or AKIN
criteria in DDs. However, these differences in allograft
function between the AKI and non-AKI groups showed
a diminishing pattern at 12 months from KT in each
analysis (Fig. 4a, b). On comparison among the three
groups, the non AKI by both criteria group showed a
superior allograft function compared to the other 2
AKI groups (AKI by KDIGO only and AKI by both cri-
teria groups) upto 6 months from KT. But, this differ-
ence also disappeared at 12 months from KT.
Meanwhile, the AKI by KDIGO only and the AKI by
both criteria groups showed a totally similar pattern to
each other through post-transplant 1 year from KT
(Fig. 4c).
Comparison of allograft survival according to the
diagnosis of AKI in corresponding DDs
The long-term allograft survival rate upto 10 years from
KT did not differ significantly between the AKI and non-
AKI groups in both analyses using the KDIGO (Fig. 5a) or
AKIN criteria (Fig. 5b) (P = 0.2, P = 0.5, respectively). On
comparison among the three groups (Non-AKI by both
criteria, AKI by only KDIGO, and AKI by both criteria
groups), no significant difference was detected (P > 0.05
for each comparison, Fig. 5c). In the Cox regression haz-
ard model, allograft survival was independently influenced
by BMI of KTRs (OR, 0.57; 95% CI, 0.41 to 0.80; P =
0.001), development of DGF (OR, 9.25; 95% CI, 1.93 to
44.33; P = 0.005), and development of acute rejection in
KTRs (OR, 6.00; 95% CI, 1.06 to 34.01; P = 0.04). However,
the development of AKI defined as the KDIGO or AKIN
criteria in DDs did not show a significant association with
allograft survival in corresponding KTRs (Table 4).
Comparison of clinical outcomes of kidney transplant
recipients according to the stage of AKI in corresponding
DDs
Based on the KDIGO criteria, DGF developed the most
frequently in the stage 3 AKI group (49% (24/49), P <
0.05 vs. stage 1, P < 0.05 vs. stage 2) followed by the
stage 1 group (26% (19/73)) (Fig. 6a). Based on the
AKIN criteria, the rate of DGF development was also
the highest in the stage 3 AKI group (62.5% (10/16), P <
0.05 vs. stage 1 (22.7% (17/75), P < 0.05 vs. stage 2
(30.8% (4/13)) (Fig. 6b). On comparison of allograft
function, it showed a stage dependently deteriorating
pattern upto 6 months from KT in both analyses using
the KDIGO or AKIN criteria. However, these differences
in allograft function according to the AKI stage nearly
disappeared at 1 year from KT in both analyses (Fig. 6c,
d). Also, the allograft survival rate did not show a signifi-
cant difference among each AKI stage group and the
non-AKI group according to either the KDIGO or AKIN
criteria (P > 0.05 for each comparison, Fig. 6e, f ).
Discussion
In this study, we compared two standardized criteria for
the diagnosis of AKI; the KDIGO and AKIN criteria in
the prediction of DGF development and also other clin-
ical outcomes in KTRs. When they were applied for the
diagnosis of AKI in DDs, the KDIGO criteria had a









Age 1.00 (0.98-1.02) 0.7
Male 3.42 (1.60-7.30) 0.002 2.30 (0.83-6.37) 0.1
BMI 1.08 (0.98-1.18) 0.1
DM 1.07 (0.34-3.36) 0.9




AKI by KDIGO 5.86 (2.37-14.47) <0.001 6.67 (1.60-27.73) 0.009
AKI by AKIN 5.95 (2.59-13.65) <0.001 8.93 (2.46-32.44) 0.001
CVP 1.08 (0.99-1.17) 0.08








Age 0.98 (0.96-1.01) 0.3
Male 1.07 (0.60-1.93) 0.8
BMI 1.01 (0.92-1.10) 0.9
DM 1.03 (0.48-2.22) 0.9
Hypertension 1.34 (0.53-3.38) 0.5
GN 1.29 (0.72-2.32) 0.4
Retransplantation
1.61 (0.67-3.85) 0.3
PRA 1.01 (1.00-1.02) 0.2







0.23 (0.13-0.48) <0.001 0.07 (0.01-1.01) 0.06
Abbreviations: CI confidence interval, BMI body mass index, DM diabetes
mellitus, CVA cerebrovascular accident, AKI acute kidney injury, KDIGO kidney
disease: improving global outcome, AKIN acute kidney injury network, CVP
central venous pressure, MAP mean arterial pressure, GN glomerulonephritis,
PRA panel reactive antibody, HLA human leukocyte antigen, MN mismatch
number, ATG anti-thymocyte globulin
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superior predictive value for the development of DGF in
corresponding KTRs in comparison with the AKIN cri-
teria. However, this higher accuracy for DGF did not re-
sult in a better prediction of long-term allograft
outcomes.
First, we compared the KDIGO criteria with the
AKIN criteria in terms of the detection rate of AKI
in DDs, and a significant discrepancy was found be-
tween the two criteria. According to the KDIGO cri-
teria, additional 39 DDs were diagnosed as having
AKI, which resulted in a higher incidence of AKI
(54.6% (106/205)) in comparison with that using the
AKIN criteria (35.6% (73/205)). In addition, a consid-
erable discrepancy was detected in the distribution of
AKI stage between the two criteria. AKI diagnosis by
KDIGO showed a higher stage distribution compared
to that of the AKI stage according to the AKIN cri-
teria (P = 0.001). Indeed, in non-AKI patients accord-
ing to the AKIN criteria, nearly 30% was defined as
AKI by the KDIGO criteria, and even more, 5% was
defined as stage 3 AKI (Fig. 2).
These discrepancies between the KDIGO and AKIN
criteria in the diagnosis of AKI in DDs may have re-
sulted from the differences in the details between two
criteria. Although both criteria are commonly based
on the change in serum creatinine and urine output,
some differences exist in detailed components be-
tween the two criteria. For example, in the KDIGO
criteria, AKI was defined as an increase in SCR to ≥1.5
times baseline, which is known or presumed to have
occurred within the prior 7 days. In contrast, increase
in SCR by ≥0.3 mg/dl within the 48 h time constraint
was necessary for the diagnosis of AKI by the AKIN
criteria [16, 22]. Therefore, use of the KDIGO criteria
can detect AKI in more patients in comparison with
the AKIN criteria as shown in a previous study per-
formed in AKI populations [17].
Fig. 4 Comparison of the change in allograft function after kidney
transplantation between the non-AKI and AKI groups according to
the diagnosis of AKI by the (a) KDIGO or (b) AKIN criteria in corre-
sponding DDs. Please note that allograft function was significantly
lower in the AKI group than in the non-AKI group by 6 months after
KT, but these differences disappeared at 1 year after KT for any AKI
criteria. c Comparison of the change in allograft function among the
three groups; non-AKI by both criteria, AKI by KDIGO only, and AKI
by both criteria groups. Please note that the changing pattern of
allograft function in the AKI by KDIGO only group was very similar to
that in the AKI by both criteria group. MDRD, the modification of
diet in renal disease; eGFR, estimated glomerular filtration rate; AKI,
acute kidney injury; DDs, deceased donors; KDIGO, kidney disease:
improving global outcome; AKIN, acute kidney injury network; KT,
kidney transplantation; d, day; m, month. *P < 0.05 compared with
non-AKI group, †P < 0.05 AKI group by KDIGO only compared with
non-AKI group, ‡P < 0.05 AKI group by KDIGO and AKIN compared
with non-AKI group
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Our next aim was to investigate whether a different
detection rate of AKI by the KDIGO criteria can re-
sult in a difference in the prediction of DGF in corre-
sponding KTRs. The incidence of DGF showed a
significant increase in the AKI group compared to the
non-AKI group, irrespective of the criteria applied in
DDs (Fig. 3a, b), which is fully consistent with many
previous studies [3, 5–7, 23, 24]. However, we mainly
were interested in the 61 KTRs who were diagnosed
as having AKI by the KDIGO criteria but not by the
AKIN criteria (the AKI by KDIGO only group), be-
cause the result in this group may differentiate the
predictive value for DGF between the KDIGO and
AKIN criteria. Interestingly, the incidence of DGF in
the AKI by KDIGO only group was very similar to
that in the AKI by both criteria group and it was sig-
nificantly higher than that in the non-AKI by both
criteria group. This suggests that the kidney functions
of patients in the AKI by KDIGO only group were
more alike to those of the AKI by both criteria group
rather than the non-AKI by both criteria group.
In addition, in the multivariate analysis using logistic
regression analysis, detection of AKI either by KDIGO
or AKIN in DDs was independently associated with
DGF in corresponding KTRs. In further analysis using
ROC analysis, both criteria significantly predicted DGF
in corresponding KTRs. However, area under the curve
in ROC analysis was significantly larger in the KDIGO
criteria than in the AKIN criteria. This is consistent
with the above findings, which showed that the inci-
dence of DGF in the AKI by KDIGO only group was
more alike to that of the AKI by both criteria group ra-
ther than that of the non-AKI by both criteria group.
All our results suggest that the KDIGO criteria may be
better in discriminating kidneys which will result in
DGF in comparison with the AKIN criteria in DDs.
Third, allograft function showed a worse value during
post-transplant 6 months in the AKI group in compari-
son with the non-AKI group in both analyses using ei-
ther the KDIGO or AKIN criteria. However, this
difference disappeared at one year from KT, similar to
that in our previous report [5]. In three group analysis,
allograft function was inferior in the AKI by both criteria
group in comparison with the non-AKI by both criteria
group, but this difference also disappeared at 1 year
from KT (Fig. 4c). Interestingly, the AKI by KDIGO only
group showed a very similar pattern of allograft function
to that in the AKI by both criteria group, which is con-
sistent with the result about DGF development. On
comparison of the long-term allograft survival rate, no
significant difference was detected between the two
groups or among the three groups, irrespective of the
applied AKI criteria as for the comparison of the 1 year
allograft function in each group. Finally, diagnosis of
AKI either by AKIN or KDIGO in DDs was not a signifi-
cant risk factor for allograft failure in a Cox regression
hazard model.
Meanwhile, the development of DGF was independ-
ently associated with allograft failure along with acute
Fig. 5 Comparison of the long-term allograft survival rate between
the non-AKI and AKI groups according to the diagnosis of AKI by
the (a) KDIGO or (b) AKIN criteria in corresponding DDs. Please note
that no difference was detected in allograft survival rate between
the AKI group and the non-AKI group in both analyses. c On com-
parison of long-term allograft survival rate among the three groups;
non-AKI by both criteria, AKI by KDIGO only, and AKI by both criteria
groups, no difference was found. AKI, acute kidney injury; DDs, de-
ceased donors; KDIGO, kidney disease: improving global outcome;
AKIN, acute kidney injury network
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rejection and recipient BMI as in many previous stud-
ies [25–27]. This suggests that even though a high in-
cidence of DGF in KT from an AKI donor did not
result in an adverse allograft outcome, DGF itself is
still an important risk factor. The exact reason for
this is unclear, but it may be because the develop-
ment of DGF in the non-AKI group is associated with
worse allograft outcomes. The development of DGF
in non-AKI kidneys from DDs is frequently due to
acute rejection not due to acute tubular necrosis,
which may explain the poor allograft outcome in
those cases [6, 28]. However, further investigation is
required to clarify this issue.
Lastly, we investigated whether the severity of AKI
in DDs has a significant impact on the clinical out-
comes of corresponding KTRs. As expected, stage 3
AKI in DDs resulted in the highest incidence of DGF
and a lower allograft function during post-transplant
6 months in corresponding KTRs compared to that in
stage 1 or 2 AKI in DDs in both analyses using the
KDIGO or AKIN criteria. However, these differences
showed a decreasing pattern in allograft function at
one year from KT, and long term allograft survival
rate did not show significant differences in compari-
son across the AKI stage both by the KDIGO or
AKIN criteria. This suggests that not only AKI diag-
nosis but also the severity of AKI in DDs may not
have a significant impact on long-term allograft out-
comes in corresponding KTRs.
Our study has some limitations. Firstly, not all re-
cipients corresponding to the donors included in this
study were included in this analysis because some
Table 4 Risk Factor for Death Censored Graft Failure
Univariate Multivariate
Odd ratio (95% CI) P value Odd ratio (95% CI) P value
Donor
Age 1.00 (0.97-1.03) 0.9
Male 1.15 (0.42-3.11) 0.8
BMI 0.89 (0.75-1.06) 0.2
DM 0.77 (0.09-6.06) 0.8
Hypertension 2.21 (0.80-6.11) 0.1
Cause of death (CVA) 1.88 (0.66-5.39) 0.2
AKI by KDIGO 0.98 (0.32-3.01) 0.9 1.37 (0.19-10.09) 0.8
AKI by AKIN 0.44 (0.13-1.45) 0.2 0.18 (0.02-1.40) 0.1
CVP 1.02 (0.89-1.16) 0.1
MAP 0.97 (0.94-1.01) 0.8
Last day urine output 1.00 (1.00-1.00) 0.4
Cold ischemic time 1.00 (0.99-1.00) 0.4
Recipient
Age 0.97 (0.92-1.02) 0.2
Male 1.15 (0.45-2.94) 0.8
BMI 0.83 (0.70-0.99) 0.03 0.57 (0.41-0.80) 0.002
DM 0.55 (0.12-2.45) 0.4
Hypertension 1.29 (0.29-5.82) 0.7
GN 1.45 (0.57-3.68) 0.4
Retransplantation 1.04 (0.23-4.75) 0.9
PRA 0.96 (0.91-1.02) 0.2
HLA MN 1.64 (1.03-2.62) 0.04
ATG (Reference = Basiliximab) 0.71 (0.16-3.18) 0.6
Tacrolimus (Reference = Cyclosporine) 0.40 (0.14-1.21) 0.1
Delayed graft function 1.95 (0.71-5.37) 0.2 9.25 (1.93-44.33) 0.005
Acute rejection 7.55 (2.86-19.91) <0.001 6.00 (1.06-34.09) 0.04
Abbreviations: CI confidence interval, BMI body mass index, DM diabetes mellitus, CVA cerebrovascular accident, KDIGO kidney disease: improving global outcome,
AKIN acute kidney injury network, CVP central venous pressure, MAP mean arterial pressure, GN glomerulonephritis, PRA panel reactive antibody HLA human
leukocyte antigen, MN mismatch number, ATG anti-thymocyte globulin
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organs were transferred to another institution accord-
ing to the organ distribution rule in Korea, which
could have induced a bias during analysis. Secondly,
this study was performed as a retrospective chart re-
view. A prospective multicenter study conducted in a
larger patient group is required to overcome the
above issues.
Conclusions
In conclusion, the KDIGO criteria may be more appro-
priate than the AKIN criteria in terms of the prediction
of DGF in corresponding KTRs. However, AKI or AKI
stage by any criteria failed to affect long-term allograft
outcomes, which suggests that AKI itself may not be a
reason for exclusion from kidney donation in DDKT.
Fig. 6 Clinical outcomes of kidney transplant recipients according to the AKI stage by either the KDIGO or AKIN criteria in corresponding donors. The
incidence of DGF was highest in stage 3 AKI by either the (a) KDIGO or (b) AKIN criteria. The changing patterns of allograft function in each AKI stage
group according to the AKI stage in corresponding donors by the (c) KDIGO or (d) AKIN criteria. Please note that allograft function was lowest in the stage
3 AKI group and highest in the non-AKI group in both analyses by 6 months after KT. But these differences disappeared at 1 year from KT. The allograft sur-
vival rate in each AKI stage group according to the AKI stage in corresponding donors by the (e) KDIGO or (f) AKIN criteria. Please note that there was no
significant difference in long term allograft survival rate among each AKI stage group in both analyses. MDRD, the modification of diet in renal disease;
eGFR, estimated glomerular filtration rate; DGF, delayed graft function; AKI, acute kidney injury; KDIGO, kidney disease: improving global outcome; AKIN,
acute kidney injury network; d, day; m, month. * P <0.05 compared with non-AKI, † P < 0.05 compared with AKI stage 1, ‡ P <0.05 compared with non-AKI,
§ P <0.05 AKI stage 1 compared with non-AKI, II P <0.05 AKI stage 3 compared with non-AKI, ¶ P <0.05 AKI stage 3 compared with non-AKI
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Abbreviations
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